Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
52-week range
$17.05 – $40.56
100% from low
Sector
Biotechnology
Centessa Pharmaceuticals plc operates as a clinical-stage pharmaceutical enterprise focused on discovering, developing, and ultimately providing therapeutic solutions to patients. The company's most advanced product candidates include Lixivaptan, a small molecule inhibitor of the vasopressin V2 receptor, which is currently undergoing Phase III clinical evaluation for treating autosomal dominant polycystic kidney disease. Additionally, SerpinPC, an activated protein C inhibitor, is progressing through Phase IIa clinical development for the management of hemophilia A and B. Centessa's pipeline also features several emerging assets in the clinical proof-of-concept stage. These comprise LB101 (a PD-L1xCD47 LockBody) and LB201 (a PD-L1xCD3 LockBody), both engineered to selectively activate potent CD47 and CD3 effector functions while minimizing systemic side effects. Another molecule, ZF874, is a small molecule pharmacological chaperone in Phase I studies, designed to correct the misfolding of the Z variant of alpha-1-antitrypsin, thus addressing alpha-1-antitrypsin deficiency. Furthermore, MGX292, a recombinant modified BMP9 replacement protein, aims to rectify the deficient BMP9 signaling implicated in Pulmonary Arterial Hypertension. The company is also developing OX2R Agonists, which are selective orexin receptor 2 agonists (available as oral and intranasal formulations) intended to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1 by leveraging structural insights. Beyond these, Centessa is exploring further clinical proof-of-concept compounds. CBS001, an anti-LIGHT antibody, is being investigated for inflammatory and fibrotic diseases due to its preferential binding to the inflammatory membrane form of LIGHT. Lastly, CBS004 is a humanized monoclonal antibody specifically targeting BDCA2, a protein found exclusively on plasmacytoid dendritic cells, with potential utility in conditions such as systemic sclerosis, systemic lupus erythematosus, and other autoimmune disorders. Centessa Pharmaceuticals plc was established in 2020 and is headquartered in Altrincham, United Kingdom.
www.centessa.comNo one on the platform currently holds CNTA.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 185,000 | $7.3M |
No one on the platform has traded CNTA yet.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | ||||||
| Profit Margin % | -1316.9% | |||||
| Free Cash Flow Margin % | -1294.6% | |||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $3M | -80.4% | $-1.64 | $-1.81–$-1.59 | — | 2 |
| 2027 | $25M | +709.7% | $-1.70 | $-1.92–$-1.56 | — | 5 |
| 2028 | $220M | +779.8% | $-1.12 | $-3.42–$1.90 | — | 6 |
| 2029 | $496M | +125.4% | $0.81 | $0.81–$0.81 | 49.8× | 3 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 2 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-05-05 | $-0.38 | $-0.52 | -36.8% |
| 2026-03-31 | $-0.37 | $-0.48 | -29.2% |
| 2025-11-05 | $-0.39 | $-0.41 | -5.1% |
| 2025-08-12 | $-0.35 | $-0.38 | -8.6% |
| 2025-05-14 | $-0.35 | $-0.20 | +42.9% |
| 2025-03-24 | $-0.38 | $-0.84 | -121.1% |
| 2024-11-12 | $-0.42 | $-0.37 | +11.9% |
| 2024-08-13 | $-0.38 |
| $-0.40 |
| -5.3% |
| -3.19% |
| $4.6B |
| — |
| GLUEMonte Rosa Therapeutics, Inc. | $13.25 | -4.64% | $1.1B | — |
| IPSCCentury Therapeutics, Inc. | $1.94 | -3.00% | $168M | — |
Source: Financial Modeling Prep · peers by sector/industry
$LLY $NVO $CNTA $CVS CVS Health (CVS) earnings Q2 2026 https://share.google/j9ebL116LBnNjI69u
View on StockTwits ↗
Eli Lilly Stock Surges 6% After Q2 Earnings Beat Driven By Mounjaro, Zepbound $LLY Also Mentions: $NVO $CNTA $CVS https://talkmarkets.com/article/eli-lilly-stock-surges-6-after-q2-earnings-beat-driven-by-mounjaro-zepbound-1785948575
View on StockTwits ↗
$CNTA Equity Corporate Actions Alert #2026 - 416 Information Regarding the Merger of Centessa Pharmaceuticals plc (CNTA) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-416 At a special meeting held on June 12, 2026, the shareholders of Centessa Pharmaceuticals plc (CNTA) approved the proposed merger with Eli Lilly and Company. The merger is tentatively scheduled to close prior to the market open on June 24, 2026. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on June 23, 2026. If the merger closes as anticipated, the stock will remain halted on the day of closing (June 24th) and will be suspended effective June 25, 2026.
View on StockTwits ↗
THINGS TO WATCH, FRIDAY, 6/12/2026 👁️ $SPCX.X $LLY $CNTA $KLAC $SPY
View on StockTwits ↗
RECAP 4/29 Unusual Puts: $CNTA Jul 35 P $BMNR Jun 15 P $ONDS Dec 6 P $CCJ May29 85 P $ONDS Jun 8 P $WMT May01 125 P Live Breaking trading news www.openoutcrier.com
View on StockTwits ↗
Eli Lilly’s Been On An Acquisition Spree This Year – Here’s A Look At Its Major Deals $LLY $CNTA https://stocktwits.com/news/equity/markets/eli-lilly-acquisition-spree-this-year-look-at-its-major-deals/cZBNxaDRePo
View on StockTwits ↗
$CNTA Centessa downgraded to Hold from Buy at Truist Truist analyst Danielle Brill downgraded Centessa (CNTA) to Hold from Buy with a $38 price target after Eli Lilly (LLY) announced an agreement to acquire the company for $38 per share in cash plus a non-transferable contingent value right worth up to $9 per share.
View on StockTwits ↗
$CNTA Price: $39.67 (-0.46%) Trend: Bullish Market Bias (7D): Bearish Bias 📉 Expected Range: ±6.06% RSI: 78.5 | Momentum: Strong Momentum Volume: -60.0% vs avg Volatility: 10.45% Support: $25.06 | Resistance: $40.26 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25
View on StockTwits ↗
KALV / PHVS potential big pharma acquisitions for hereditary angioedema (HAE) treatments. $APLS $DAWN $FOLD $EXAS $CNTA . BEP energy play.
View on StockTwits ↗
$CNTA Stock analysis https://youtu.be/DKJlY-cIfwo?si=d8brZd4Aq_Muj25T
View on StockTwits ↗
$LLY just made a $7.8B move — and it’s not about obesity 👀 Lilly is acquiring $CNTA for $6.3B upfront (up to $7.8B with CVRs), adding a pipeline of OX2R agonists led by cleminorexton in mid-stage trials for narcolepsy and IH — a clear push to diversify beyond its GLP-1 dominance 💊 Centessa stock surged 44% on the news, while Lilly gained ~4%, signaling strong market approval of the strategy. Latest LLY news here 👉 https://www.zacks.com/stock/quote/LLY?cid=sm-stocktwits-0-quote_overview-oc-37620&ADID=SYND_STOCKTWITS_TWEET_0_QUOTEOVERVIEW_OC_37620
View on StockTwits ↗
🚀 Bulls in full charge today! 🐂🔥 Huge congrats to everyone riding these top movers on March 31: $FLY +20% – Space stocks lifting off on SpaceX IPO buzz and sector momentum! $APLS +135% – Biogen acquiring Apellis for $5.6B in a blockbuster immunology deal! $CNTA +44% – Eli Lilly snapping up Centessa for up to $7.8B to boost sleep-wake disorder pipeline! Epic green day – keep stacking those gains, bulls! 💪📈 Who else is celebrating? #TopMovers #BullMarket #Stocks
View on StockTwits ↗
Top Gainers PT2 $KIDZ $GVH $WSHP $CNTA $HKIT
View on StockTwits ↗
Eli Lilly Just Made a $7 Billion Bet on the Future of Sleep: https://www.smartinvestornews.com/all-articles/eli-lilly-just-made-a-7-billion-bet-on-the-future-of-sleep $LLY $CNTA
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.